India, Sept. 25 -- The treatment landscape for type 2 diabetes has evolved significantly in recent years. As care has expanded beyond blood sugar control to include the reduction of cardiovascular and kidney complications, glucagon-like peptide-1 (GLP-1) receptor agonists have become an important part of diabetes management. Alongside innovation and expanding access, quality is another factor increasingly shaping clinical conversations.

For complex therapies such as GLP-1 receptor agonists, quality goes far beyond the active ingredient. "It is built into every stage of a medicine's development, from the science behind the molecule and the manufacturing process to the strength of the clinical evidence supporting its use", Dr M.V.Rama Moha...